We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for afamelanotide (Clinuvel Pharmaceuticals Ltd)
Active ingredients
afamelanotide
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Subcutaneous implant
Indication
For the treatment of erythropoietic porphyrias